Brain	brain	O	O	O	O
natriuretic	natriuretic	O	O	O	O
peptide	peptide	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
predictor	predictor	O	O	O	O
of	of	O	O	O	O
anthracycline-induced	anthracycline-induced	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Anthracyclines	anthracyclines	O	O	OTHERS	I
are	are	O	O	O	O
effective	effective	O	O	O	O
antineoplastic	antineoplastic	CHEMICALS	O	OTHERS	I
drugs	drugs	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
but	but	O	O	O	O
they	they	O	O	O	O
frequently	frequently	O	O	O	O
cause	cause	O	O	O	O
dose-related	dose-related	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
conventional	conventional	O	O	O	O
anthracycline	anthracycline	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
highlights	highlights	O	O	O	O
a	a	O	O	O	O
need	need	O	O	O	O
to	to	O	O	O	O
search	search	O	O	O	O
for	for	O	O	O	O
methods	methods	O	O	O	O
that	that	O	O	O	O
are	are	O	O	O	O
highly	highly	O	O	O	O
sensitive	sensitive	O	O	O	O
and	and	O	O	O	O
capable	capable	O	O	O	O
of	of	O	O	O	O
predicting	predicting	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
measured	measured	O	O	O	O
the	the	O	O	O	O
plasma	plasma	O	O	O	O
level	level	O	O	O	O
of	of	O	O	O	O
brain	brain	O	O	O	O
natriuretic	natriuretic	O	O	O	O
peptide	peptide	O	O	O	O
(	(	O	O	O	O
BNP	bnp	O	O	O	O
)	)	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
whether	whether	O	O	O	O
BNP	bnp	O	O	O	O
might	might	O	O	O	O
serve	serve	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
simple	simple	O	O	O	O
diagnostic	diagnostic	O	O	O	O
indicator	indicator	O	O	O	O
of	of	O	O	O	O
anthracycline-induced	anthracycline-induced	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
acute	acute	O	O	OTHERS	I
leukemia	leukemia	O	O	OTHERS	I
treated	treated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
daunorubicin	daunorubicin	CHEMICALS	O	OTHERS	I
(DNR)-containing	(dnr)-containing	O	O	O	O
regimen	regimen	O	O	O	O
.	.	O	O	O	O

Thirteen	thirteen	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
acute	acute	O	O	OTHERS	I
leukemia	leukemia	O	O	OTHERS	I
were	were	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
DNR-containing	dnr-containing	O	O	O	O
regimen	regimen	O	O	O	O
.	.	O	O	O	O

Cardiac	cardiac	O	O	O	O
functions	functions	O	O	O	O
were	were	O	O	O	O
evaluated	evaluated	O	O	O	O
with	with	O	O	O	O
radionuclide	radionuclide	O	O	O	O
angiography	angiography	O	O	O	O
before	before	O	O	O	O
chemotherapies	chemotherapies	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
plasma	plasma	O	O	O	O
levels	levels	O	O	O	O
of	of	O	O	O	O
atrial	atrial	O	O	O	O
natriuretic	natriuretic	O	O	O	O
peptide	peptide	O	O	O	O
(	(	O	O	O	O
ANP	anp	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
BNP	bnp	O	O	O	O
were	were	O	O	O	O
measured	measured	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
time	time	O	O	O	O
of	of	O	O	O	O
radionuclide	radionuclide	O	O	O	O
angiography	angiography	O	O	O	O
.	.	O	O	O	O

Three	three	O	O	O	O
patients	patients	O	O	O	O
developed	developed	O	O	O	O
congestive	congestive	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
after	after	O	O	O	O
the	the	O	O	O	O
completion	completion	O	O	O	O
of	of	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
.	.	O	O	O	O

Five	five	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
diagnosed	diagnosed	O	O	O	O
as	as	O	O	O	O
having	having	O	O	O	O
subclinical	subclinical	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
after	after	O	O	O	O
the	the	O	O	O	O
completion	completion	O	O	O	O
of	of	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
plasma	plasma	O	O	O	O
levels	levels	O	O	O	O
of	of	O	O	O	O
BNP	bnp	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
clinical	clinical	O	O	O	O
and	and	O	O	O	O
subclinical	subclinical	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
increased	increased	O	O	O	O
above	above	O	O	O	O
the	the	O	O	O	O
normal	normal	O	O	O	O
limit	limit	O	O	O	O
(	(	O	O	O	O
40	40	O	O	O	O
pg/ml	pg/ml	O	O	O	O
)	)	O	O	O	O
before	before	O	O	O	O
the	the	O	O	O	O
detection	detection	O	O	O	O
of	of	O	O	O	O
clinical	clinical	O	O	O	O
or	or	O	O	O	O
subclinical	subclinical	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
by	by	O	O	O	O
radionuclide	radionuclide	O	O	O	O
angiography	angiography	O	O	O	O
.	.	O	O	O	O

On	on	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
hand	hand	O	O	O	O
,	,	O	O	O	O
BNP	bnp	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
without	without	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
given	given	O	O	O	O
DNR	dnr	O	O	OTHERS	I
,	,	O	O	O	O
even	even	O	O	O	O
at	at	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
700	700	O	O	O	O
mg/m(2	mg/m(2	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
plasma	plasma	O	O	O	O
level	level	O	O	O	O
of	of	O	O	O	O
ANP	anp	CHEMICALS	O	OTHERS	I
did	did	O	O	O	O
not	not	O	O	O	O
always	always	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
clinical	clinical	O	O	O	O
and	and	O	O	O	O
subclinical	subclinical	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
.	.	O	O	O	O

These	these	O	O	O	O
preliminary	preliminary	O	O	O	O
results	results	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
BNP	bnp	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
useful	useful	O	O	O	O
as	as	O	O	O	O
an	an	O	O	O	O
early	early	O	O	O	O
and	and	O	O	O	O
sensitive	sensitive	O	O	O	O
indicator	indicator	O	O	O	O
of	of	O	O	O	O
anthracycline-induced	anthracycline-induced	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

